SNNA Description — Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s primary product candidates from its technological platform are SNA-120 (pegcantratinib), a first-in-class TrkA inhibitor for the topical treatment of psoriasis, as well as the associated pruritus; and SNA-125, a topical JAK3/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and the associated pruritus. Co.'s second technology platform, Topical Photoparticle Therapy, utilizes silver particles applied to the skin to direct the light from commercially available lasers to the hair follicle or sebaceous gland to cause selective photothermolysis.